Peptide Protocol
Peptide Protocol
 App Store

Semaglutide: the complete guide

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It slows gastric emptying, enhances insulin secretion, and reduces appetite.

Written by Peptide Protocol Editorial Medically reviewed per our review process Last reviewed
ClassGLP-1 receptor agonist
Half-lifeApproximately 7 days (once-weekly dosing)
Typical doseTitration: 0.25 mg (250 mcg) → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly
CategoryGLP-1 / metabolic
Research useWeight management, glycemic control, metabolic research
FDA statusFDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny.

How Semaglutide works

Semaglutide mimics endogenous glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors in the pancreas (boosting glucose-dependent insulin release) and in the hypothalamus (suppressing appetite).

Typical Semaglutide dosage

Commonly reported research ranges: Titration: 0.25 mg (250 mcg) → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly.

Dose should always be individualized. Factors that influence it include bodyweight, research goal, tolerance, and specific compound batch. The information below is educational, not a prescription.

How to reconstitute Semaglutide

A widely used reconstitution for a 5 mg vial is 2 ml of bacteriostatic water. With a typical 250 mcg dose this works out to the unit count shown in the calculator below.

Open the Semaglutide reconstitution calculator →

Pre-filled with the common 5 mg + 2 ml ratio. Adjust for your own vial.

Half-life and administration frequency

Approximately 7 days (once-weekly dosing).

This half-life informs how often Semaglutide is typically dosed. Shorter half-lives usually mean more frequent dosing to maintain plasma levels; longer half-lives allow daily, weekly, or less-frequent administration depending on the compound.

Reported side effects

This list reflects effects reported in available literature or user logs. It is not exhaustive. Adverse reactions should be discussed with a qualified clinician.

Common Semaglutide stacks

Full editorial stack guides featuring Semaglutide:

Semaglutide + Tesamorelin

Recomposition alongside GLP-1 fat loss, targeting visceral fat, users losing too much lean mass on Semaglutide alone.

Fat lossRecomposition

Semaglutide + Cagrilintide

Users who plateau on semaglutide alone, pursuing tirzepatide-range weight loss without switching classes, clinical replications of the CagriSema program.

Fat lossMetabolic

Storage and handling

Lyophilized stable refrigerated. Reconstituted: refrigerated 2–8 °C, use within 28 days.

FDA and regulatory status

FDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny.

Semaglutide clinical trials and evidence

For clinical-trial and primary-literature context, start with the sources below. We prioritize official drug labels, ClinicalTrials.gov records, and PubMed-indexed literature when available.

Track your Semaglutide protocol on iPhone

Peptide Protocol logs every dose, calculates reconstitution for you, and keeps your full protocol on one calm screen.

See the app →

Frequently asked questions

What is Semaglutide?

Semaglutide is a long-acting GLP-1 receptor agonist approved for type 2 diabetes and chronic weight management. It slows gastric emptying, enhances insulin secretion, and reduces appetite.

How does Semaglutide work?

Semaglutide mimics endogenous glucagon-like peptide-1 (GLP-1), binding to GLP-1 receptors in the pancreas (boosting glucose-dependent insulin release) and in the hypothalamus (suppressing appetite).

What is a typical Semaglutide dose?

Commonly reported ranges are Titration: 0.25 mg (250 mcg) → 0.5 mg → 1.0 mg → 1.7 mg → 2.4 mg weekly. This is research information, not a recommendation — dosing should be individualized under clinical guidance.

What is the half-life of Semaglutide?

Approximately 7 days (once-weekly dosing). This influences how often it is administered.

How do you reconstitute Semaglutide?

A common approach is to add 2 ml of bacteriostatic water to a 5 mg vial. Use the reconstitution calculator for exact unit counts.

What are the side effects of Semaglutide?

Nausea (very common, especially during dose escalation); Constipation or diarrhea; Fatigue; Injection-site reactions; Rare: pancreatitis, gallbladder issues.

Is Semaglutide FDA approved?

FDA approved as Ozempic (type 2 diabetes), Wegovy (obesity), Rybelsus (oral T2D). Compounded semaglutide is not FDA approved and is under active FDA scrutiny.

Are there clinical trials for Semaglutide?

Registered or published clinical-trial sources for Semaglutide are listed in the references section below. Evidence depth varies widely by compound, so check the cited trial registries and primary literature before relying on any claim.

References

  1. Ozempic / Wegovy / Rybelsus prescribing information (FDA Drugs@FDA) — U.S. Food and Drug Administration. Official FDA-approved labeling for semaglutide products
  2. STEP and SUSTAIN trial programs (ClinicalTrials.gov) — ClinicalTrials.gov. Phase 3 obesity (STEP) and diabetes (SUSTAIN) trial records
  3. Semaglutide clinical literature (PubMed) — National Library of Medicine. Primary literature on GLP-1 receptor agonist pharmacology and outcomes

Sources listed above were used to verify the claims on this page. See our editorial policy for how we source information.

Educational use only. Peptide Protocol is an informational tool. Nothing on this page constitutes medical advice. Many peptides are prescription-only or restricted in your jurisdiction. Always consult a licensed healthcare professional before injecting any compound.